Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive drug comparison in infants with hypoxic-ischemic encephalopathy
IRCT20110807007244N10Phase 3Recruiting
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of allopurinol and erythropoietin in hypoxic-ischemic encephalopathy (HIE) (4 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Change in pro-oxidant-antioxidant balance, Change in interleukin-6 and 1 more. Started Feb 2024; status: recruiting.
02
Drugs
allopurinolerythropoietin
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on IRCT20110807007244N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20110807007244N10.